SCHEMBL1780342

SCHEMBL1780342

O=C1CCC(OCc2ccccc2)CC1c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
AR P10275 1/20 0.38
FFAR1 O14842 1/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
XBP1 P17861 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
S1PR1 P21453 2/20 0.36
MGLL Q99685 1/20 0.36
IDO1 P14902 2/20 0.36
CXCR3 P49682 1/20 0.35
OPRK1 P41145 1/20 0.35
SLC6A9 P48067 1/20 0.35
KCNA5 P22460 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779644 0.78 SLC18A3 (0.41) PPARGPPARAFFAR1GAAMAPT
SCHEMBL1779542 0.73 CCR2 (0.45) PPARGPPARAMGLLIDO1CXCR3
SCHEMBL1783202 0.73 CCR2 (0.45) PPARGPPARAMGLLIDO1CXCR3
SCHEMBL1779964 0.71 NOTUM (0.40) FFAR1KMT2A
SCHEMBL1138534 0.71 ABCC9 (0.41) ARIDO1OPRK1SLC6A9
SCHEMBL2774615 0.70 PSEN1 (0.45) KMT2APSEN1PSEN2APH1BNCSTN
SCHEMBL5696636 0.69 AR (0.44) ARKMT2AS1PR1
SCHEMBL6963769 0.68 PSEN1 (0.45) KMT2APSEN1PSEN2APH1BNCSTN
SCHEMBL19642819 0.66 PSEN1 (0.46) KMT2APSEN1PSEN2APH1BNCSTN
SCHEMBL27860439 0.66 PSEN1 (0.46) KMT2APSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507559-B2 Cyclohexenyl modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-13 US disclosed
EP-2318352-B1 CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2012-12-19 EP disclosed
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
EP-2318352-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2011-05-11 EP disclosed
WO-2010009068-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR1, CCR2, CCR3 PPARG 605/4885PPARA 1419/4885AR 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.